At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Arcus Biosciences stock faces an October 20 casdatifan data event covering 121 late-line patients. Q

Arcus Biosciences recently announced it would host an in-person investor event on October 20, 2026, in New York City to present new ARC-20 platform data on its investigational HIF-2a inhibitor casdatifan across first-, second-, and late-line clear cell renal cell carcinoma treatment settings. A particularly important aspect is the breadth of casdatifan data, including TKI-free first-line combinations, long-follow-up second-line cabozantinib combinations, and translational HIF-2a...

Price-action only: Arcus Biosciences Inc. (RCUS) movements set the tone for institutional models. Behavioral Patterns of RCUS and Institutional Flows

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

En Yahoo Finance, obtienes cotizaciones de acciones gratuitas, noticias actualizadas, recursos de gestión de carteras, datos de mercados internacionales, interacción social y tasas hipotecarias que te ayudarán a gestionar tu vida financiera.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

HAYWARD, Calif., September 24, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price per share of $26.39, which was the closi

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Las acciones de Arcus Biosciences generaron ingresos de 41 millones de dólares en el segundo trimestre de 2026 frente a 21,98 millones de dólares consensuados.

HAYWARD, Calif., September 24, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price per share of $26.39, which was the closi